S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:VXRTVaxart Stock Price, Forecast & News

$9.09
-0.11 (-1.20 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.93
Now: $9.09
$9.59
50-Day Range
$2.66
MA: $10.03
$16.97
52-Week Range
$0.25
Now: $9.09
$17.49
Volume10.37 million shs
Average Volume16.82 million shs
Market Capitalization$992.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.29
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Read More
Vaxart logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.86 million
Book Value$0.27 per share

Profitability

Net Income$-18,650,000.00
Net Margins-281.50%

Miscellaneous

Employees34
Market Cap$992.65 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$9.09
-0.11 (-1.20 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock been impacted by Coronavirus (COVID-19)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 339.1% and is now trading at $9.09.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vaxart?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart
.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Vaxart
.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.06. Vaxart had a negative return on equity of 104.25% and a negative net margin of 281.50%.
View Vaxart's earnings history
.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

3 brokers have issued 12-month price targets for Vaxart's stock. Their forecasts range from $6.00 to $22.00. On average, they expect Vaxart's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price.
View analysts' price targets for Vaxart
.

Has Vaxart been receiving favorable news coverage?

News articles about VXRT stock have trended extremely negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Vaxart
.

Are investors shorting Vaxart?

Vaxart saw a increase in short interest in June. As of June 30th, there was short interest totaling 6,770,000 shares, an increase of 65.5% from the June 15th total of 4,090,000 shares. Based on an average daily volume of 17,320,000 shares, the days-to-cover ratio is presently 0.4 days.
View Vaxart's Short Interest
.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (0.37%), UBS Group AG (0.28%), Prudential Financial Inc. (0.27%), Hussman Strategic Advisors Inc. (0.18%), Bank of New York Mellon Corp (0.11%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart
.

Which institutional investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, and Todd C Davis.
View insider buying and selling activity for Vaxart
.

Which institutional investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, Bank of New York Mellon Corp, Russell Investments Group Ltd., National Asset Management Inc., Rathbone Brothers plc, and New York State Common Retirement Fund. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart
.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $9.09.

How big of a company is Vaxart?

Vaxart has a market capitalization of $992.65 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.